ATXS Overview

Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.

Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Astria Therapeutics Inc revenue for the last quarter amounts to 706.00K USD, decreased

Astria Therapeutics Inc. EPS for the last quarter amounts to -0.55 USD, increased 30.95

Astria Therapeutics Inc (ATXS) has 78 emplpoyees as of March 16 2026.

Today ATXS has the market capitalization of 506.30M USD.